Welcome to our dedicated page for Beigene news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on Beigene stock.
BeiGene Ltd (NASDAQ: BGNE) is a global biotechnology leader pioneering innovative oncology therapies through its integrated research and clinical trial model. This page serves as the definitive source for verified company developments, offering stakeholders timely access to essential updates.
Find comprehensive coverage of BeiGene's progress in cancer treatment innovation, including clinical trial milestones, regulatory submissions, and strategic collaborations. The curated news collection enables efficient tracking of the company's pipeline advancements in checkpoint inhibitors and targeted small molecule therapies.
Key updates include quarterly financial results, manufacturing expansions, and peer-reviewed research publications. All content undergoes rigorous verification to ensure accuracy in reporting scientific developments and corporate announcements.
Bookmark this page for direct access to BeiGene's latest press releases and analysis of their unique CRO-free clinical development approach, a strategic differentiator in global biopharmaceutical operations.
BeiGene, a global oncology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The event will feature a fireside chat at 1:20 pm EDT, accessible via live webcast through BeiGene's investor relations websites. The replay will be available for 180 days post-event.
BeiGene announced new analyses for BRUKINSA® (zanubrutinib) at the ASCO Annual Meeting 2024. The data underline BRUKINSA's efficacy and safety in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) compared to other BTK inhibitors (BTKis).
A network meta-analysis highlighted BRUKINSA's superior progression-free survival (PFS) over acalabrutinib in high-risk relapsed/refractory CLL patients. Additional findings indicated a trend towards better overall survival (OS) and overall response (ORR) rates.
A retrospective analysis from Kaiser Permanente revealed that BRUKINSA is well-tolerated, with lower treatment-limiting adverse events, particularly cardiac-related, compared to ibrutinib. A post-hoc analysis of the ALPINE trial showed patients on BRUKINSA had less frequent initiation of new antihypertensive medications.
Overall, BRUKINSA demonstrates a favorable clinical profile, offering significant insights for oncologists in treatment decision-making for CLL and SLL patients.
BeiGene announced it will present new data from its hematology portfolio at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024.
Highlights include 28 abstracts, with four oral presentations. Key studies focus on BRUKINSA® (zanubrutinib), sonrotoclax, and BGB-16673. BRUKINSA, in combination with venetoclax, showed strong efficacy and favorable safety in high-risk CLL/SLL patients.
Sonrotoclax demonstrated promising safety and efficacy as a monotherapy and in combination therapies, particularly with BRUKINSA. Also, BGB-16673, a BTK degrader, showed encouraging results in BTK inhibitor-resistant diseases.
These findings underscore BeiGene's commitment to advancing treatment options for B-cell malignancies and other hematological conditions.
BeiGene reported total revenues of $752 million in the first quarter of 2024, with product revenue reaching $747 million, an 82% increase from the prior-year period. BRUKINSA revenue was $489 million, showcasing growth in the U.S. and Europe. The company is focusing on advancing its late-stage hematology pipeline, improving operating leverage, and aiming for sustainable profitability. Key updates include the FDA approval for BRUKINSA in follicular lymphoma and the sales growth of TEVIMBRA in various indications. The company also highlighted progress in its hematology and solid tumor programs, along with key pipeline advancements in lung, breast, and gastrointestinal cancers.
FAQ
What is the current stock price of Beigene (BGNE)?
What is the market cap of Beigene (BGNE)?
